Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 30, 2019 07:00 ET | Source: Scilex Holding Company

Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak

PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors...
September 30, 2019 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR to Present at Two Investor Conferences in October

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
September 30, 2019 02:30 ET | Source: F. Hoffmann-La Roche Ltd

Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa

Efficacy of Alecensa® (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the...
September 30, 2019 01:05 ET | Source: F. Hoffmann-La Roche Ltd

FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders

Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitisThese two forms of...
September 30, 2019 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 30 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously...
September 28, 2019 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer

New real-world data from the Flatiron database supports clinical benefits of Alecensa® (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival...
September 27, 2019 10:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer

Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy aloneData will...
September 27, 2019 08:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma

The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic...
September 27, 2019 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting

WATERTOWN, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
September 27, 2019 01:30 ET | Source: NICOX

Nicox Completes Enrolment of NCX 4251 Phase 2 Trial with Top-Line Results on Track for Q4 2019

Press ReleaseNicox Completes Enrolment of NCX 4251 Phase 2 Trial with Top-Line Results on Track for Q4 2019 September 27, 2019 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext...